Cinacalcet Tablet
Product Images NDC 69097-411

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 69097-411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 01

Chemical structure of cinacalcet hydrochloride, showing the molecular arrangement including trifluoromethyl and naphthyl groups connected to an amine hydrochloride moiety.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 02

A line graph depicting parathyroid hormone (PTH) levels over 26 weeks, comparing placebo and cinacalcet tablets. The x-axis represents weeks, and the y-axis measures PTH in pg/mL. The chart shows decreasing PTH levels with cinacalcet tablets and relatively stable or slightly increasing levels with placebo.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 03

A line graph depicting calcium x phosphorus (Ca x P) levels in mg/dL over a 26-week period. Two lines are shown: one for Placebo with black dashed lines and another for Cinacalcet tablets in red solid lines, with error bars at each time point. The graph illustrates changes in Ca x P levels for both treatment groups over time.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 04

A line chart depicting calcium levels (in mg/dL) over weeks of treatment in patients with parathyroid carcinoma. The graph shows data from baseline through titration and maintenance phases, with calcium levels plotted against time in weeks and including error bars for variability.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 05

A line graph depicting serum calcium levels (mg/dL) over 80 weeks during titration, end of treatment (EOT), and maintenance phases. The x-axis represents time in weeks, with markers for intractable pHPT cases below. The y-axis measures calcium concentration, showing trends and variability over time.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 06

Label for Cinacalcet Hydrochloride Tablets 30 mg, supplied as a package of 30 tablets. The label indicates it is Rx only, manufactured by Cipla Ltd. in India and labeled for Cipla USA Inc. It includes storage instructions, barcode, and space for batch overprinting of serial number, expiration date, and lot number.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 07

Label for Cinacalcet Hydrochloride Tablets 60 mg by Cipla USA Inc., containing 30 film-coated tablets. Each tablet contains cinacalcet hydrochloride equivalent to 60 mg cinacalcet. The label includes storage instructions, manufacturer details, barcode, and reserved space for batch overprinting including serial number, expiry, and lot information.*

FDA Label Image

00722e4a 7103 49ef 8cfd 6a14b0088f0e 08

Label for Cinacalcet Hydrochloride Tablets 90 mg by Cipla. The label indicates 30 film-coated tablets, with each containing 99 mg cinacalcet hydrochloride equivalent to 90 mg cinacalcet. It includes storage instructions at 25°C and mentions dosage directions as per package insert. Manufactured by Cipla Ltd., India and labeled for Cipla USA, Inc., Warren, NJ. The label includes a barcode and QR code with an area designated for batch overprinting.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.